Anna Ivanova

Prof. Anna Ivanova


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
AVAnastasia Voznesenskaya
Anastasia Voznesenskaya
ASAlena Sorokina
Alena Sorokina
MSMarina Shestakova
Marina Shestakova
ESEkaterina Shestakova
Ekaterina Shestakova
IMIldar R. Minniakhmetov
Ildar R. Minniakhmetov
MLMarina Yu Loguinova
Marina Yu Loguinova
Of the many clinical phenotypes of obesity the most prevalent are metabolically “healthy” (MHO) and metabolically “unhealthy” obesity (MUO), the latter being associated with a range of comorbidities, in-cluding type 2 diabetes mellitus (T2DM). The underlying causes of different obesity phenotypes and the mechanisms of conversion of one phenotype into another, have yet to be fully elucidated. However, in-creasing evidence suggests the key role of low-grade metabolic inflammation (metaflammation) in patho-genesis of obesity and metabolic dysfunction. This review compares numerous pro-inflammatory media-tors observed in MHO and MUO to identify the role of metaflammation in obesity phenotype. A mechanis-tic model is proposed for the progression from MHO to MUO with the exacerbation of metaflammation and dysfunction of insulin-sensitive organs. MUO is characterized by the excess of visceral adiposity, both local and systemic insulin resistance (IR). Obesity is accompanied by a shift in the immune profile from anti-inflammatory to pro-inflammatory, with its worsening in MUO. However no clinically significant pa-rameter has been identified among soluble factors or leukocyte subtypes in the blood as a predictor of MHO to MUO conversion. Structural and functional changes in adipose tissue are not resolved immediately following bariatric interventions. The persistence of «metabolic memory» in the form of epigenetic modi-fications in macrophages of adipose tissue and the emergence of large numbers of CD4+ and CD8+ effec-tor memory T cells with senescent phenotype, may predispose to weight regain and T2DM relapse post-surgery. The review discusses mechanisms underlying metabolic memory and potential reversibility of metabolic disturbances after bariatric surgery.

20 May 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
AVAnastasia Voznesenskaya
Anastasia Voznesenskaya
ASAlena Sorokina
Alena Sorokina
MSMarina Shestakova
Marina Shestakova
ESEkaterina Shestakova
Ekaterina Shestakova
IMIldar R. Minniakhmetov
Ildar R. Minniakhmetov
MLMarina Yu Loguinova
Marina Yu Loguinova
Of the many clinical phenotypes of obesity, the most prevalent are metabolically “healthy” (MHO) and metabolically “unhealthy” (MUO) obesities, the latter being associated with a range of comorbidities, including type 2 diabetes mellitus (T2DM). The underlying causes of different obesity phenotypes and the mechanisms of conversion of one phenotype into another have yet to be fully elucidated. However, increasing evidence suggests the key role of low-grade metabolic inflammation (metaflammation) in the pathogenesis of obesity and metabolic dysfunction. The review presents a comprehensive description of changes in immune cell populations and pro-inflammatory mediators, as well as a detailed comparative mapping of the adipose tissue immune landscape during MHO/MUO transition. Based upon a conceptual model for the intensification of metaflammation during MHO progression and conversion to MUO, a pattern of dynamical changes that accompany MHO/MUO transition is described. Though many parameters demonstrate significant differences in multiple cross-sectional and some longitudinal studies, only a few of them (CRP, IL-6, IL-17A, absolute counts of leukocytes and neutrophils) meet the criteria of a validated biomarker in clinical setting. A lack of standardization in MHO definition and heterogeneity in the severity of MUO make the search for predictive biomarkers a challenge. The review also discusses the mechanisms underlying metabolic memory and the incomplete reversibility of metabolic disturbances after bariatric surgery.

22 October 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
APAlyssa Pekonidi
Alyssa Pekonidi
NSNikita Sergeev
Nikita Sergeev
AFArtem Fedorinin
Artem Fedorinin
DLDmitry Laptev
Dmitry Laptev
MSMargarita Samsonova
Margarita Samsonova
NMNatalia G. Mokrysheva
Natalia G. Mokrysheva
Background: Type 1 diabetes mellitus (T1DM) is characterised by substantial heterogeneity in clinical manifestations, the rate of β-cell destruction, and diabetes-associated autoantibody (DAA) profiles across individuals of different ethnic backgrounds and ages. We investigated the immunological heterogeneity of T1DM through immunophenotyping of major lymphocyte populations using multiparameter flow cytometry. Results: T1DM associates with distinct immunophenotypes dependent on age, disease stage, DAA profiles, and the presence of Diabetic Ketoacidosis (DKA). Paediatric T1DM (n = 49) shows attenuated innate immunity (fewer NK and MAIT cells) alongside higher T-cell activation. Adult T1DM (n = 55) features remodelling in NK-cell receptor landscape, specifically expanding CD8+, CD38+, CD161+, and NKG2A+ NK-cell subsets. Long-standing T1DM (n = 28) combines higher CD8+ T-cell cytotoxicity with lower NK-cell cytotoxicity. High Autoantibody / Multi-antibody T1DM is marked by fewer CD8+ T cells, B cells, protective NKregs, and MAIT cells, but more CD38+ NK cells. Seronegative / Low Antibody T1DM shows a drop in total NK and NKeff cells, but an expansion of inhibitory, CD56bright, and CD8+ NK subsets. Paediatric DKA is linked to fewer innate-like T cells and more activated T cells. Adult DKA is characterized by drops in various NK cells (CD3-CD56+, CD3-CD8+, NKeff) and specific T cells (CD8+CD161+ and CD161+ double-negative). Conclusions: The immunological heterogeneity identified in patients with T1DM underscores the importance of patient stratification, which may facilitate the discovery of predictive and prognostic cellular biomarkers capable of estimating the rate of progression to clinically manifest T1DM and the risk of an aggressive disease course, respectively.